Pharmaceutical industry compliance obligations have increased dramatically over the last several years. In light of this, it is critical that companies have policies and procedures that address industry-sponsored publications activities as well as documenting and responding to medical inquiries. This session will provide an overview of recent corporate integrity agreements with a focus on industry -sponsored publication and medical communications obligations. Additionally the speakers will discuss what policies, procedures, and programs companies should consider implementing to help mitigate risk in the area of industry-sponsored publications and medical communications activities.